相似文献
1
Channeling Hope in the Expanding Landscape of Therapy for Pulmonary Hypertension: Potential Role for Piezo2.
Hypertension. 2025 Apr;82(4):598-600. doi: 10.1161/HYPERTENSIONAHA.125.24570. Epub 2025 Mar 19.
2
Loss of lung microvascular endothelial Piezo2 expression impairs NO synthesis, induces EndMT, and is associated with pulmonary hypertension.
Am J Physiol Heart Circ Physiol. 2022 Nov 1;323(5):H958-H974. doi: 10.1152/ajpheart.00220.2022. Epub 2022 Sep 23.
3
Deficiency of Endothelial Impairs Pulmonary Vascular Angiogenesis and Predisposes Pulmonary Hypertension.
Hypertension. 2025 Apr;82(4):583-597. doi: 10.1161/HYPERTENSIONAHA.124.22948. Epub 2025 Jan 6.
4
Piezo2 channel in nodose ganglia neurons is essential in controlling hypertension in a pathway regulated directly by Nedd4-2.
Pharmacol Res. 2021 Feb;164:105391. doi: 10.1016/j.phrs.2020.105391. Epub 2020 Dec 19.
5
Upregulation of Piezo2 in the mesangial, renin, and perivascular mesenchymal cells of the kidney of Dahl salt-sensitive hypertensive rats and its reversal by esaxerenone.
Hypertens Res. 2023 May;46(5):1234-1246. doi: 10.1038/s41440-023-01219-9. Epub 2023 Feb 21.
6
Piezo2 Is a Key Mechanoreceptor in Lung Fibrosis that Drives Myofibroblast Differentiation.
Am J Pathol. 2025 Apr;195(4):626-638. doi: 10.1016/j.ajpath.2024.12.015. Epub 2025 Jan 22.
7
Upregulation of Piezo2 and increased extracellular matrix protein in diabetic kidney disease mice.
Hypertens Res. 2025 Apr;48(4):1514-1528. doi: 10.1038/s41440-024-02082-y. Epub 2025 Jan 20.
8
Piezo2 is not an indispensable mechanosensor in murine cardiomyocytes.
Sci Rep. 2022 May 17;12(1):8193. doi: 10.1038/s41598-022-12085-9.
9
Prognostic Evaluation of Piezo2 Channels in Mammary Gland Carcinoma.
Cancers (Basel). 2024 Jun 29;16(13):2413. doi: 10.3390/cancers16132413.
10
The potential role of Piezo2 in the mediation of visceral sensation.
Neurosci Lett. 2016 Sep 6;630:158-163. doi: 10.1016/j.neulet.2016.07.058. Epub 2016 Jul 30.
本文引用的文献
1
Deficiency of Endothelial Impairs Pulmonary Vascular Angiogenesis and Predisposes Pulmonary Hypertension.
Hypertension. 2025 Apr;82(4):583-597. doi: 10.1161/HYPERTENSIONAHA.124.22948. Epub 2025 Jan 6.
2
Sotatercept: New drug on the horizon of pulmonary hypertension.
Vascul Pharmacol. 2024 Dec;157:107442. doi: 10.1016/j.vph.2024.107442. Epub 2024 Nov 19.
3
LOXL2 inhibition ameliorates pulmonary artery remodeling in pulmonary hypertension.
Am J Physiol Lung Cell Mol Physiol. 2024 Oct 1;327(4):L423-L438. doi: 10.1152/ajplung.00327.2023. Epub 2024 Jul 16.
4
Pulmonary Hypertension and Anastrozole (PHANTOM): A Randomized, Double-Blind, Placebo-Controlled Trial.
Am J Respir Crit Care Med. 2024 Nov 1;210(9):1143-1151. doi: 10.1164/rccm.202402-0371OC.
5
Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension.
N Engl J Med. 2023 Apr 20;388(16):1478-1490. doi: 10.1056/NEJMoa2213558. Epub 2023 Mar 6.
6
Linoleic acid improves PIEZO2 dysfunction in a mouse model of Angelman Syndrome.
Nat Commun. 2023 Mar 1;14(1):1167. doi: 10.1038/s41467-023-36818-0.
7
Piezo1, a novel therapeutic target to treat pulmonary arterial hypertension.
Front Physiol. 2023 Jan 26;14:1084921. doi: 10.3389/fphys.2023.1084921. eCollection 2023.
8
Cross-talk between TSC2 and the extracellular matrix controls pulmonary vascular proliferation and pulmonary hypertension.
Sci Signal. 2022 Dec 6;15(763):eabn2743. doi: 10.1126/scisignal.abn2743.
9
Sex Differences in Pulmonary Hypertension.
Front Aging. 2021 Oct 4;2:727558. doi: 10.3389/fragi.2021.727558. eCollection 2021.
10
A Phase-2 NIH-sponsored Randomized Clinical Trial of Rituximab in Scleroderma-associated Pulmonary Arterial Hypertension Did Not Reach Significance for Its Endpoints: End of Story? Not So Fast!
Am J Respir Crit Care Med. 2021 Jul 15;204(2):123-125. doi: 10.1164/rccm.202103-0612ED.
Zotero 插件